22 corporates have crossed the growth of IPM for the month of February 2015 amongst top 50
Indian Pharmaceutical Market (IPM) has clocked Rs 7194 crores in February 2015 and has grown at 18.9 per cent. Amongst the top 10, Cipla grew by 24 per cent followed by Lupin at 23.2 per cent and Pfizer at 22.6 per cent. 22 corporates have crossed the growth of IPM for the month of February 2015 amongst top 50.
Amongst the top 50 corporates, Akumentis has the highest growth of 52.5 per cent followed by Macleods at 39.4 per cent and JBCPL at 38 per cent. 45 corporates have shown growths more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, Macleods has the highest growth of 39.4 per cent followed by Glenmark at 33.3 per cent and Torrent at 30.8 per cent.
|
With Bonus Units at Full Value
|
(Val in Crs)
|
|||||||
|
Val in Crs
|
Rank
|
MAT Feb -15
|
Feb-15
|
|||||
|
CORPORATE
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
| IPM |
85012
|
100.00
|
11.8
|
7194
|
100.00
|
18.9
|
||
| Abbott + Abbott HC + Novo |
1
|
1
|
5281
|
6.21
|
8.8
|
470
|
6.53
|
21.1
|
| Sun Pharma |
2
|
2
|
4627
|
5.44
|
14.5
|
388
|
5.39
|
15.8
|
| Cipla |
3
|
3
|
4262
|
5.01
|
14.1
|
380
|
5.29
|
24.0
|
| Zydus + Biochem |
4
|
4
|
3647
|
4.29
|
8.7
|
301
|
4.18
|
8.0
|
| Mankind |
5
|
6
|
3058
|
3.60
|
14.2
|
246
|
3.42
|
18.7
|
| Alkem + Cachet + Indchemie |
6
|
5
|
3042
|
3.58
|
13.4
|
247
|
3.44
|
17.8
|
| Glaxo |
7
|
7
|
2993
|
3.52
|
-1.0
|
238
|
3.31
|
5.6
|
| Ranbaxy |
8
|
10
|
2983
|
3.51
|
7.2
|
227
|
3.15
|
4.0
|
| Lupin |
9
|
8
|
2866
|
3.37
|
15.2
|
234
|
3.26
|
23.2
|
| Pfizer |
10
|
11
|
2564
|
3.02
|
15.7
|
220
|
3.06
|
22.6
|
| Macleods |
11
|
9
|
2513
|
2.96
|
28.8
|
227
|
3.16
|
39.4
|
| Emcure + Zuventus |
12
|
12
|
2290
|
2.69
|
12.1
|
192
|
2.68
|
12.2
|
| Intas |
13
|
13
|
2242
|
2.64
|
16.7
|
191
|
2.65
|
20.4
|
| Sanofi India |
14
|
14
|
2150
|
2.53
|
10.9
|
185
|
2.57
|
30.7
|
| Aristo |
15
|
15
|
2127
|
2.50
|
18.1
|
183
|
2.55
|
28.0
|
| Torrent |
16
|
17
|
1934
|
2.28
|
14.1
|
174
|
2.41
|
30.8
|
| Glenmark |
17
|
16
|
1896
|
2.23
|
16.9
|
179
|
2.49
|
33.3
|
| Dr. Reddys |
18
|
18
|
1793
|
2.11
|
10.4
|
152
|
2.11
|
16.1
|
| USV |
19
|
19
|
1662
|
1.96
|
18.6
|
139
|
1.93
|
25.1
|
| Micro + Bal |
20
|
20
|
1660
|
1.95
|
8.5
|
136
|
1.89
|
12.3
|
| Ipca |
21
|
24
|
1215
|
1.43
|
20.9
|
90
|
1.25
|
35.9
|
| Novartis |
22
|
23
|
1163
|
1.37
|
2.0
|
91
|
1.27
|
2.6
|
Amongst the 51-60 ranked corporates, Centaur grew at 33.4 per cent followed by Allergan at 30 per cent and Wanbury at 24.3 per cent. Amongst the 61-70 ranked corporates, Boehringer grew by 88.5 per cent followed by TTK at 31.2 per cent and Tablets India at 30 per cent.
Indian companies have grown at 19.4 per cent versus 17.6 per cent for MNCs in February 2015. Amongst the top 50 in MNCs, Merck grew by 32.2 per cent followed by Sanofi at 30.7 per cent and MSD at 24.5 per cent. Under the Non-NLEM category, Indian companies grew at 20.8 per cent whereas MNCs grew at 17.7 per cent.
The DPCO containing molecules market grew at 13.9 per cent whereas the non-DPCO market grew by 20 per cent and non -Sch Para 19 Market at 14.4 per cent resulting in an overall growth of 18.9 per cent for February 2015. The NLEM and Non – NLEM category showed unit growth at 7.6 per cent and 10.1 per cent respectively. The Non-Sch Para 19 market grew at 9.9 per cent from units perspective. The DPCO 2013 portfolio for Pfizer grew at 21.1 per cent, Ranbaxy 20.7 per cent and Abbott 18.3 per cent.
|
Val in Crs
|
MAT Feb-15
|
Month Feb-15
|
||
|
Super Group
|
Val in Crs
|
GR%
|
Val in Crs
|
GR%
|
| IPM |
85012
|
11.8
|
7194
|
18.9
|
| ANTI-INFECTIVES |
13558
|
8.2
|
1150
|
19.6
|
| CARDIAC |
10557
|
12.1
|
896
|
16.6
|
| GASTRO INTESTINAL |
9765
|
12.9
|
796
|
19.1
|
| VITAMINS / MINERALS / NUTRIENTS |
7700
|
11.7
|
615
|
14.9
|
| RESPIRATORY |
6687
|
12.7
|
659
|
25.4
|
| ANTI DIABETIC |
6536
|
23.6
|
580
|
32.7
|
| PAIN / ANALGESICS |
5967
|
10.4
|
479
|
15.7
|
| NEURO / CNS |
5150
|
8.8
|
431
|
13.8
|
| DERMA |
4882
|
15.9
|
406
|
18.0
|
| GYNAECOLOGICAL |
4272
|
7.1
|
349
|
10.4
|
| OPHTHAL / OTOLOGICALS |
1562
|
13.2
|
127
|
17.2
|
| HORMONES |
1424
|
5.9
|
118
|
11.2
|
| VACCINES |
1420
|
-1.2
|
133
|
30.5
|
| ANTI-NEOPLASTICS |
1373
|
22.6
|
109
|
7.9
|
| BLOOD RELATED |
952
|
4.6
|
75
|
9.1
|
| OTHERS |
916
|
14.2
|
90
|
38.3
|
| UROLOGY |
901
|
23.0
|
74
|
26.7
|
| ANTI MALARIALS |
550
|
6.3
|
34
|
19.5
|
| SEX STIMULANTS / REJUVENATORS |
470
|
5.2
|
43
|
15.0
|
| STOMATOLOGICALS |
371
|
13.3
|
32
|
21.1
|
From the therapy perspective, nine therapies have outgrown the IPM growth and 18 therapies have double digit growths. The respiratory market grew at 25.4 per cent, gastrointestinal market grew at 19.1 per cent, pain and analgesics market grew at 15.7 per cent whereas the anti-infectives grew at 19.6 per cent. The anti-diabetic market grows at 32.7 per cent and cardiac at 16.6 per cent in chronic business. The derma market grew by 18 per cent and urology market at 26.7 per cent.
From regional perspective, 16 regions have outgrown the IPM growth. Madhya Pradesh market grew the highest at 28.8 per cent followed by South Rajasthan market at 27 per cent and Telangana market at 26.3 per cent. No regions had negative growth in February 2015.
Amoxycillin + Clavulanic Acid market grew at 24.7 per cent whereas Glimepiride + Metformin grows at 17.2 per cent at number two position. The markets of paracetamol grew at 28.9 per cent, Atorvastatin 17.2 per cent, Probiotic Microbes at 19.6 per cent, Cefixime 21.3 per cent, Pantoprazole 20.1 per cent, Montelukast + Levocetrizine at 33.5 per cent, Glimepiride + Metformin + Pioglitazone at 31.3 per cent, Vitamin-D at 37.3 per cent, Hydroquinone + Mometasone + Tretinoin at 10.6 per cent, Voglibose + Metformin + Glimepiride at 60.2 per cent, Rosuvastatin at 26.9 per cent, protein supplements at 23 per cent.
Glycomet-GP grew at 23.6 per cent, Augmentin at 24 per cent, Monocef at 23.5 per cent, Dexorange at 21.4 per cent and Lantus at 32.9 per cent amongst the top 10 brands.
Few brands who have gained ranks include Pentaxim (+171), Januvia (+69), Janumet (+67), Shelcal (+54), Magnex (+52), Clexane (+50), Panderm Plus (+46), Jalra M (+43), Istamet (+40), Monocef – O (+27), Dolo (+23), Rosuvas (+19), Udilive & Tonact (+18), Pan D (+15), Taxim (+8), Pan (+3), Sinarest (+2) amongst top 100 brands over February 2014.
A total of 144 brands were launched in February 2015. The top new brands for February are Materna, Rosuvas CV and Dienofem.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net